Figure 3
Analyses based on the alterations identified in the baseline plasma sample. Kaplan-Meier analysis comparing patients showing pathogenic alterations (red) vs non-pathogenic alterations (i.e., no genetic alteration or alterations identify as non-pathogenic) (blue), (a) overall survival (b) event free survival. Kaplan-Meier analysis comparing patients showing KRAS mutations (red) vs no KRAS mutations (blue), (c) overall survival (d) event free survival. +Represents the censored patients. (e) Comparison of the proportion of patients with disease control (white) vs no control (grey) in those with pathogenic alterations vs with non-pathogenic alterations (i.e., no genetic alteration or alterations identified as non-pathogenic). (f) Comparison of the proportion of patients with disease control (white) vs no control (grey) in those with KRAS mutation vs no KRAS mutation.
